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 Uveitis is traditionally described as an inflammation of
the uveal tract and anatomically categorized as anterior, inter-
mediate, posterior, or pan uveitis. However, other structures
including the retina and vitreous are frequently involved in
the inflammatory process. It is a relatively common inflam-
matory eye condition with reported annual incidence between
11.4 and 52.4 per 100,000 and prevalence between 38 and
730 per 100,000 [1-5]. Uveitis predominantly affects patients
in the working age group, that is between 21 to 60 years [6].
Despite current advances in diagnosis and management, vi-
sual loss occurs in 35-40% of patients with uveitis [7].
Although anterior uveitis is the most common form of
intraocular inflammation, intermediate, posterior and pan uvei-
tis have an increased incidence of visual morbidity. These are
characterized by inflammation of choroid, retina, retinal ves-
sels, vitreous, and ciliary body either in isolation or as a part
of pan uveitis. For this group the term posterior segment in-
traocular inflammation (PSII) has been adopted [8]. PSII or
posterior segment uveitis (PSU) can be either infectious or
immune-mediated in origin. Immune-mediated PSII accounts
for 22% to 38% of all cases of uveitis seen in tertiary care
centers [9-12]. The term covers a range of clinical phenotypes,
such as idiopathic intermediate uveitis and birdshot retinopa-
thy, but all share the same underlying immune etiology and
are immuno-phenotypically similar [13]. An animal model for
PSU has been developed that has greatly increased our knowl-
edge of immunopathology and various subgroups involved in
this group [14]. Immune-mediated PSII is broadly divided into
two categories depending upon the presence of associated sys-
temic disease. Patients with sarcoidosis, Behcet’s disease, or
multiple sclerosis can develop PSII, and each manifestation
has its own clinical and immunopathological features. How-
ever, patients with idiopathic intermediate uveitis, white dot
syndromes, and multifocal choroiditis share the same pathol-
ogy, have no associated systemic features, and are considered
to have idiopathic posterior segment uveitis (IPSU). Studies
have shown the inflammatory process in IPSU is perpetuated
by a Th1-mediated inflammatory response [13-16], but what
triggers the uveitis initially and why certain groups of people
are more susceptible than others is not known.
The genetic predisposition to develop uveitis has long been
investigated. The association of HLA genes, particularly HLA-
A29 in birdshot chorioretinopathy and HLA-B27 in anterior
uveitis, is well known, but the mechanisms of disease induc-
tion remain elusive. Recently, attention has been focused on
single nucleotide polymorphisms (SNPs) in the genes con-
trolling the inflammatory processes in immune-mediated dis-
eases. Some SNPs may alter protein structure and function
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Purpose: Chemokines are important inflammatory mediators that play a crucial role in uveitis. Polymorphisms in chemokine
genes can alter the expression of these genes in the inflammatory cells, which, in turn, can affect the clinical phenotype of
the disease. The purpose of this study was to identify polymorphisms in chemokine genes that can predict visual outcome
in patients with immune-mediated posterior segment uveitis.
Methods: This is a case-control study of 141 Caucasians with idiopathic immune-mediated posterior segment uveitis and
282 controls matched by age and ethnicity. Six polymorphisms in four genes, (MCP-1-2518A/G, RANTES-403G/A,
RANTES-28C/G, CCR2 V64I, CCR5-59029G/A, and CCR5 32 bp deletion) were analyzed by sequence specific primers
polymerase chain reaction.
Results: Patients with G allele at MCP-1-2581 developed the disease at an early age as compared to patients with A allele
corrected p value pc=0.003. Also patients with A allele at RANTES-403 position developed less severe disease and had
better visual outcome when compared with patients with G allele (pc=0.02) Final visual acuity after 18 months was better
in patients with 32 bp deletion of the CCR5 gene and in patients with the CCR2 wild-type genotype pc=0.02 and pc=0.04,
respectively. Patients with the CCR2 64I allele also had a higher risk of developing an elevated intraocular pressure as
compared to patients with the wild-type genotype (pc=0.007).
Conclusions: Though the utility for prediction of disease susceptibility of the studied polymorphisms in chemokine genes
is in general not robust, we have found that polymorphisms in chemokine genes can influence the outcome of patients
with idiopathic immune-mediated posterior segment uveitis. These associations require further analysis in other groups of
patients.
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388through a single nucleotide base substitution in a gene’s cod-
ing region, or may increase or decrease gene expression ei-
ther by affecting mRNA stability when occurring in a gene’s
3' untranslated region or by altering transcription factor bind-
ing when occurring in the 5' promoter region.
Chemokines, which are chemo-attractive cytokines, are
one type of the many proteins involved in the inflammatory
process. They have been shown to play a critical role in the
development of inflammation in diverse immune-mediated dis-
ease models [17-19]. Similarly their role in ocular inflamma-
tion is becoming more clear; they have been shown to be pro-
duced by ocular cells cultured in vitro, and monocyte
chemoattractant protein-1 (MCP-1, now known as CCL2),
RANTES (CCL5) and interleukin-8 (IL-8) have been detected
in ocular fluids and tissues during intraocular inflammation
[20-25]. Human retinal pigment epithelial cells (RPE) and reti-
nal microvascular endothelial cells are also able to produce
these chemokines [23,26-28].
Animal studies of PSU have shown that CCR5 is a recep-
tor of various chemokines like RANTES, MIP-1α, and MIP-
1β plays a crucial role in the migration of Th1 cells to the site
of inflammation [29]. Increased expression of CCR2 (recep-
tors for MCP-1/CCL2) and CCR5 genes on posterior segment
extracts have also been found in animal models of posterior
uveitis [30].
Quite a few functional polymorphisms have been discov-
ered in these chemokine genes particularly in the promoter
regions. Promoter polymorphisms at the -2518A/G position
of the MCP-1 gene [31] -28C/G and -403G/A of the RANTES
gene [32,33], and -59029G/A of the CCR5 gene [34] have
been shown to affect the expression of genes and have been
noted to affect the phenotype of various immune-mediated
diseases. A SNP at position 46295 has been identified in the
open reading frame of CCR2. The G/A substitution leads to
replacement of valine by isoleucine at amino acid 64 (CCR2
V64I) in the first transmembrane domain of CCR2 [35]. Al-
though this change is considered to be non-functional, it has
been found to be associated with various immune-mediated
diseases particularly sarcoidosis [36]. Another widely reported
polymorphism is the CCR5 32 bp deletion mutation (del. 32)
within the coding sequence of the extracellular loop of the
CCR5 gene. This polymorphism also affects gene expression
[37] and has been noted to be protective in many immune-
mediated diseases [38,39].
Although many studies have demonstrated association of
these SNPs with various immune-mediated diseases, such as
sarcoidosis and Behcet’s, the evidence in uveitis is lacking. At
least two studies have investigated the role of MCP-1-2518A/
G, RANTES-28C/G, -403G/A and CCR5 del. 32 in uveitis in
Behcet’s disease [40,41], but no particular association has been
identified. To explore the role of chemokine SNPs in IPSU,
we examined whether these six polymorphisms (MCP-1-
2518A/G, RANTES-28C/G and -403G/A, CCR2 V64I, CCR5-
59029G/A, and CCR5 del. 32) were associated with IPSU.
The aim was determine whether these polymorphisms can af-
fect disease phenotype and predict visual outcome and response
to treatment.
METHODS
 This study was approved by the Ethics Committee of
Moorfields Eye Hospital and was conducted according to the
tenets of the Declaration of Helsinki. After giving informed
consent, patients with IPSU were recruited from the uveitis
clinic at Moorfields Eye Hospital in London. IPSU was de-
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TABLE 1. PRIMERS USED IN DETECTING SINGLE NUCLEOTIDE POLYMORPHISM IN CHEMOKINE GENES
                                                                                  Product
                                                                                   size
       SNP            Chromosome    Identity            Primer (5'-3')             (bp)
-------------------   -----------   ---------   -------------------------------   -------
MCP-1 -2518A/G        17q11.2-q12   rs1024611   F: AAGTGGGAGGCAGACAGCTA/G         252
                                                R: CTGATAAAGCCACAATCCAGAG
RANTES -403G/A        17q11.2-q12   rs2107538   F: CATGGATGAGGGAAAGGAGG/A         285
                                                R: GAGTCTCTGTCTCTCCCTCA
RANTES -28C/G         17q11.2-q12   rs2280788   F: GCCCTTTATAGGGCCAGTTG/C         314
                                                R: GTCCTAACTGCCACTCCTTG
CCR2 V64I             3p21          rs1799864   F: TTTTTGCAGTTTATTAAGATGAGGAC/T   808
                                                R: GAAGGCAGAAGGTGAATAGTTC
CCR5 -59029G/A        3p21          rs2040388   F: ACTTCACATTAACCCTGTGC/T         712
                                                R: ACTGTCATTCAGCCCAATACC
CCR5 32 bp deletion   3p21                      F: GCTCTCATTTTCCATACAGTCAG/A      827/808
                                                R: TATACATAAGGAACTTTCGGAGTG
The single nucleotide polymorphism (SNPs) were detected in 141 patients and 282 controls by sequence specific primers polymerase chain
reaction (SSP-PCR) method. SSP-PCR utilizes SSPs with 3'-end mismatches and identifies the presence of specific allelic variants through
PCR amplification.
389fined as a noninfectious inflammation of the choroid, retina,
retinal vessels, vitreous, or ciliary body in the absence of any
known systemic disease. By definition, this excluded patients
with sarcoid associated uveitis, Behcet’s-associated uveitis,
Vogt-Koyanagi-Harada disease as well as patients with mul-
tiple sclerosis or any other identified systemic disease. A com-
plete ophthalmic examination was undertaken that included
valuation of visual acuity, intraocular pressures, dilated fun-
dus, and an anterior segment slit-lamp examination. Where
necessary, fundus fluorescein angiography, optical coherence
tomography, B scan, and visual field tests were performed.
Clinical details were obtained for each patient and in-
cluded the following: age of onset, follow up period, laterality
of disease, type and pattern of posterior uveitis, visual acuity,
and ocular complications that can reduce vision such as cata-
ract, glaucoma, cystoid macular edema (CME), optic atrophy,
and retinal detachment. We also took into consideration the
duration and amount of systemic steroids, second line immu-
nosuppressive agents, and intra-vitreal/periocular steroids used
to control intraocular inflammation.
Visual loss was defined as, the loss of two Snellen lines
from baseline or a visual acuity of 6/12 or worse. Visual loss
caused by macular scar, optic nerve changes, macular ischemia,
and choroidal neovascular membrane was considered to be
permanent visual loss. The amount of visual impairment was
used to classify intensity of the disease which was defined as
visual impairment during the episode of inflammation and at-
tributed directly to the inflammatory process or its complica-
tions. It was graded into moderate or severe inflammation,
with Snellen VA loss of 6/60 or worse taken as severe inflam-
mation. Elevated intraocular pressure was defined as a persis-
tently high intraocular pressure of more than 21 mm Hg as a
direct result of inflammation. By definition it excluded ste-
roid responders and any spikes of high intraocular pressure
due to intra-vitreal or periocular corticosteroids.
Controls:  For comparison, the control population con-
sisted of 282 healthy Caucasians aged 60 or older, who were
admitted for age-related cataract surgery and had no previous
ocular disease or immune-mediated disease.
DNA extraction and genotyping:  Genomic DNA was ex-
tracted from 10 ml EDTA-chelated peripheral whole blood,
using commercial kits (Qiagen UK Ltd, Crawley, West Sus-
sex, UK) according to the manufacturer’s instructions. To iden-
tify potential SNPs, we compared multiple sequences for MCP-
1, RANTES, CCR2, and CCR5 deposited in GenBank. When
sequence differences were identified, these were regarded as
potential SNPs and were further investigated. To verify the
presence of each putative polymorphism, the SNPs were de-
termined on a series of pooled Caucasian DNA samples using
sequence-specific primers polymerase chain reaction (SSP-
PCR) method [42]. SSP-PCR utilizes SSPs with 3'-end mis-
matches and identifies the presence of specific allelic variants
through PCR amplification. In brief, each reaction contained
5 µl of the appropriate primer mix (allele-specific and control
primers) and 8 µl PCR reaction mixture, containing 1X PCR
buffer (Bioline, London, UK), 300 µM of each
deoxynucleotide triphosphate (Bioline), 2 mM MgCl2, 0.32 U
Taq polymerase (Bioline), and 0.01 to 0.1 µg DNA per well.
The final volume of 13 µl was overlaid with 10 µl mineral oil
in every PCR reaction. The DNA mixtures were heated at 96
°C for 1 min in the first round of denaturation and then sub-
jected to 5 cycles of 25 s at 96 °C, 45 s at 70 °C, and 25 s at 72
°C; this was then followed by 21 cycles of 25 s at 96 °C, 50 s
at 65 °C, 30 s at 72 °C; and finally 4 cycles of 30 s at 96 °C, 60
s at 55 °C, 90 s at 72 °C. All PCR amplifications were carried
out under identical conditions in a PTC200 thermal cycle
(model PTC200; Bio-Rad-MJ Research, Herts, UK). PCR
products were then analyzed by electrophoresis on a 1% aga-
rose gel. A positive reaction was defined as the presence of an
allele-specific band of the expected size in conjunction with a
control band. The absence of an allele-specific band in the
presence of a control band was considered to be a negative
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TABLE 2. DEMOGRAPHIC AND CLINICAL DETAILS OF THE 141 PATIENTS
-----------------------------------------   -------------   ------------------------
Follow up in years                          Mean=6.8        Range=(1.5-42.6)
Sex                                         Males=59        Females=82
Laterality of disease                       Bilateral=118   Unilateral=23
Age of onset (years)                        Mean=37.82      Range=(5-70.5)
Recurrence (rate per year)                  Mean=1.92       Range=(1-7)
MeanVisual impairment during inflammation   Mean=6/12       Range=(6/5-PL)
Best corrected vision after 18 months       Mean=6/9        Range=(6/5-HM)
Permanent visual loss                       n=55            Mean=6/24, Range=6/12-HM
More than 10 mg of steroids for long term   n=51
On second line of immuno-suppressants       n=51
Cystoid macular edema                       n=85
Raised intra-ocular pressure                n=46
Cataract                                    n=55
141 patients with idiopathic posterior segment uveitis were included
in this study. The follow up ranged from 1.5-42.6 years. This table
summarizes the clinical details of the patients.
TABLE 3. GENOTYPIC FREQUENCIES OF CHEMOKINE SINGLE NUCLE-
OTIDE POLYMORPHISMS IN PATIENTS AND CONTROLS
                                Patients   Controls
        Genotype                n=(141)    n=(282)
-----------------------------   --------   --------
MCP-1 -2518 A/G       AA        58.2%       53.4%
                      AG        36.9%       38.5%
                      GG        5.0%        8.1%
RANTES -403 G/A       GG        61.0%       63.3%
                      GA        34.8%       31.8%
                      AA        4.3%        4.9%
RANTES -28 C/G        CC        94.3%       94.3%
                      CG        5.7%        5.3%
                      GG        0.0%        0.4%
CCR2 V64I             VV        82.3%       87.2%
                      VI        16.3%       12.5%
                      II        1.4%        0.4%
CCR5 -59029 G/A       GG        21.3%       22.3%
                      GA        44.7%       48.6%
                      AA        34.0%       29.1%
CCR2 32 bp deletion   wt/wt     77.3%       76.6%
                      wt/del    20.6%       21.6%
                      del/del   2.1%        1.8%
The genotypic frequencies of the six polymorphisms were compared
between patients and controls. The frequencies are shown in per-
centage and as seen in the table there are no significant differences
between the genotypic frequencies of patients and controls.
390reaction. The primers used are shown in Table 1.
Statistical analysis:  For each subject group, genotype
frequencies were counted and the allelic and allele carriage
frequencies calculated. All genotype frequencies in each popu-
lation were tested for deviation from the Hardy-Weinberg equi-
librium using the χ-square test. Data mining for significant
associations was performed using Knowledge Seeker®,
(Angoss softwares, Guilford, UK), and statistical calculations
were performed with with statistical Package for social sci-
ences SPSS V 12.0 (Chicago, IL). Confidence intervals were
calculated at the 95% level and a value of p<0.05 was consid-
ered as significant. χ-square test was used to compare the ge-
notypic and allelic frequencies in patients and controls. A cor-
rection for multiple comparisons was made using the
Bonferroni method, adding the formula pc=p x n where pc
represents the corrected value, p is the uncorrected value, and
n is the numbers of comparisons performed. A multiple logis-
tic regression model was used to determine association be-
tween various genotypes and the phenotypes.
For statistical purpose no attempt was made to divide the
IPSU group into clinical subgroups as the groups would be
meaningless for the statistical analysis. However whenever
any association of a clinical sign, phenotype, or type of uvei-
tis was noted with a SNP, multiple logistic regression model
was used to correct the p value for the type of uveitis besides
other parameters. Power calculations were performed using
Quanto Version 1.0, which is specifically designed for use in
genetic studies. Quanto is freely available from the following
website (Hydra).
RESULTS
 This study used 141 patients with IPSU. The mean age of
onset of IPSU was 37.8 years. The female to male ratio was
1.4: 1. The demographic and clinical details are shown in Table
2. Among the groups the patients with pan uveitis had worse
visual acuity compared to the others after first year of onset of
disease (p=0.03) but the difference was not significant after
the third year and onwards. There was also significant differ-
ence in the treatment given to the patients among the different
groups. Patients with intermediate uveitis had more localized
corticosteroid therapy (peri-ocular and intra-vitreal steroids)
compared to other groups (p=0.01). Similarly permanent vi-
sual loss and high intraocular pressure were more common in
pan uveitis patients compared to other patients. Hence when
determining the association of these variables with genotypes,
the statistical correction was done using multiple logistic re-
gression. All genotype frequencies in the study conformed to
Hardy-Weinberg equilibrium. The genotype frequencies of all
six SNPs in PSU and controls are shown in Table 3.
Risk of developing uveitis:  There was no significant dif-
ference in the genotypic frequencies between the controls and
IPSU. Subgroup analysis also did not reveal any association
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TABLE 4. ALLELIC FREQUENCIES OF CHEMOKINE SINGLE NUCLEOTIDE POLYMORPHISMS IN MAJOR SUBGROUPS OF IDIOPATHIC POSTERIOR SEGMENT
UVEITIS
                              Intermediate    Pan      Posterior    Grand
                                uveitis      uveitis    uveitis    Vasculitis   total
         Genotype               n=(77)       n=(17)  n=(29)   n=(18)  n=(141)
---------------------------   ------------   -------   ---------   ----------   -------
MCP-1 -2518 A/G     AA            53%         71%        69%         50%          58%
                    AG            43%         18%        28%         44%          37%
                    GG            4%          12%        3%          6%           5%
RANTES -403 G/A     GG            58%         71%        59%         67%          61%
                    GA            40%         24%        31%         28%          35%
                    AA            1%          6%         10%         6%           4%
RANTES -28 C/G      CC            95%         88%        93%         100%         94%
                    CG            5%          12%        7%          0%           6%
CCR2 V64I           VV            79%         76%        93%         83%          82%
                    VI            18%         24%        7%          17%          16%
                    II            3%          0%         0%          0%           1%
CCR5 -59029 G/A     GG            25%         6%         17%         28%          21%
                    GA            40%         47%        66%         28%          45%
                    AA            35%         47%        17%         44%          34%
CCR5 32 bp deletion wt/wt         81%         76%        72%         72%          77%
                    wt/del        17%         18%        28%         28%          21%
                    del/del       3%          6%         0%          0%           2%
Idiopathic posterior segment uveitis was divided into four types on the basis of site of inflammation. Subgroup analysis did not reveal any
association of chemokine SNPs with any phenotype of uveitis apart from CCR2 64I allele, which was slightly higher in patients with interme-
diate uveitis (12%) when compared to the controls (7%; p=0.03, pc=0.09). The genotypic frequencies are shown in percentages.
391of chemokine SNPs with any phenotype of IPSU apart from
CCR2 64I allele, which was slightly higher in patients with
intermediate uveitis (12%) when compared to the controls (7%;
p=0.03, pc=0.09). The allelic frequencies in the subgroups are
shown in Table 4.
Effect on phenotype:  When the influence of genotypes
on the clinical phenotype of the patients were compared, it
was found that the MCP-1-2518 G allele was significantly
associated with a younger age of onset of disease. The mean
age of diesase onset in patients with the AA genotype was 41
years compared to 33 years in patients with the G allele car-
riage (pc=0.003). This difference was still significant after cor-
recting for type of IPSU pc=0.006. It was also noted that the
RANTES-403 polymorphism was associated with the disease
severity (VA impairment of 6/60 or less during an episode of
active inflammation), and this difference was still significant
when corrected for uveitis type, disease duration, and treat-
ment received. Severe inflammatory episodes were seen in
38% (33/86) of the patients with the GG genotype as com-
pared to 20% (11/55) in patients with the A allele carriage.
(pc=0.04 OR=0.40, 95% CI=0.18-0.88). The G allele was also
significantly associated with worst visual acuity in the affected
eye. As shown in Table 5 patients with the GG genotype had a
worse mean visual acuity as compared to carriers of the A
allele after a ten year period.
The CCR5 del. 32 was found to be associated with visual
outcome even after correction for disease phenotype and treat-
ment. No patient with a final VA of 6/12 or worse was found
to be homozygous for del. 32. The mean VA after 18 months
(which was the minimum follow-up period) in patients with
wild-type genotype was 6/9 where as it was 6/6 in patients
with del. 32 allele (pc=0.04). The frequency of the 32 del.
allele in patients with VA 6/9 or better was 15% compared to
3% in the group with a VA of 6/12 or worse (p=0.01, pc=0.028)
corrected for age, type of uveitis, treatment and duration of
disease. CCR2 V64I, which is strongly linked to the CCR2 32
bp deletion, also showed association with visual outcome. The
patients with CCR2 64VV had a mean visual acuity of 6/9
after 18 months compared to 6/15 among patients with 64I
allele carriage. After correction for uveitis type, treatment, and
patient age, the difference was still significant (pc=0.04). It
was also noted that among carriers of the I allele 60% (15/25)
of the patients developed elevated intraocular pressure com-
pared to 26.7% (31/116) of the patients with the wild-type
genotype (p=0.001, OR 4.11; 95%CI: 1.67-10.11). After cor-
rection for the treatment, patient age, disease type, and dura-
tion, the pc was 0.007. CCR5 -59029 SNP was associated with
the need for persistent corticosteroid therapy of more than 10
mg per day to control inflammation. We found 20% (6/30) of
the patients with the wild type GG allele had received long-
term corticosteroid treatment compared to 39.6% (44/111) of
patients with A allele carriage p=0.046 which remained sig-
nificant after correcting for duration of disease and type of
uveitis p=0.05. The summary of these finding is shown in Table
6.
DISCUSSION
 In this study, we investigated the potential significance of the
CC chemokines MCP-1 and RANTES and their receptors
CCR2 and CCR5 in immune-mediated PSU by analyzing the
association of genetic polymorphisms of these four genes with
the clinical outcome in patients with PSU. The aim of the study
was to see whether these functional SNPs could affect the clini-
cal outcome of PSU independent of uveitis type. The results
show that polymorphisms in chemokine genes can affect the
disease phenotype in PSU.
The MCP-1-2518 G mutation is known to increase the
expression of the MCP-1 gene [30]. Many studies have shown
an association of this allele with immune-mediated diseases
[43,44] and anterior uveitis [45]. The frequency of G allele in
the controls was 23% which is similar to previous reported
studies [31,46]. No significant difference was noted in the
genotypic frequencies between the control and IPSU popula-
tions. Interestingly however, we found that the carriage of the
G allele was associated with disease development at an earlier
age compared to patients with no G allele. A multiple logistic
regression analysis showed that the G allele was not corre-
lated to any specific disease group, and hence after correction
for type of uveitis the association was still significant. Although
it is difficult to say how this allele can affect the age of onset,
it is important to note similar results have been documented
in other diseases that also show association of MCP-1-2518 G
allele with early onset of disease [47].
Enhancement of RANTES gene expression has been ob-
served with the presence of the -28G allele and the -403A
allele [32,33]. The -403A and -28G alleles have been associ-
ated with various immune-mediated diseases [48-52] but we
did not detect any significant difference in the genotypes be-
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TABLE 5. COMPARISON OF MEAN VISUAL ACUITIES BETWEEN RANTES -403 GG AND RANTES -403 GA/AA OVER A TEN-YEAR PERIOD
               Mean VA     Mean VA     Mean VA     Mean VA    Mean VA
  Genotype     at year 1   at year 2   at year 3   at year 5   at year 10
------------   ---------   ---------   ---------   ---------   ----------
RANTES GG       0.5103      0.4824      0.4817      0.4155       0.3844
RANTES GA/AA    0.7140      0.6783      0.6726      0.6213       0.5422
P value         0.002       0.013       0.016       0.026        0.056
(2-tailed)
The G allele of RANTES -403 SNP was significantly associated with worst visual acuity in the affected eye. As shown in this table patients
with the GG genotype had a worse mean visual acuity as compared to carriers of the A allele. The difference was greater in early years but even
after 10 years of onset of disease the patients with A allele carriage had better mean visual acuity.
392tween the IPSU patients and controls. The frequencies of both
SNPs in patients and controls were similar to other published
studies [32,51]. As shown by other studies [53], the two SNPs
were in linkage disequilibrium. RANTES -28 G/G was not
found in subjects with -403 G allele, and RANTES -403G/G
was not observed in subjects with -28 G allele. PSU patients
with the -403A allele developed less intense inflammation (as
judged by amount of visual impairment during an inflamma-
tory episode) compared to patients with the wild-type geno-
type. We also observed that patients with A allele carriage had
better visual acuity compared to GG genotype at least for 10
years after the onset of uveitis. It appears that the -403A al-
lele, which is associated with increased RANTES expression,
has a protective effect in patients with PSU. This is in contrast
with other studies where the A allele was found to be associ-
ated with increased disease susceptibility and severity [47-
50]. Recently Sonoda et al. [54] showed that in experimental
autoimmune uveitis (EAU), which is the animal model for
posterior uveitis, RANTES produced by ocular macrophages
appears to have a suppressive effect. In another study [55]
RANTES levels remained high during the recovery phase of
autoimmune anterior uveitis associated with experimental
autoimmune encephalomyelitis (EAE), and treatment with
anti-RANTES antibodies was not effective in suppressing the
uveitis. These studies show that decreased levels of RANTES
may be associated with prolonged severe inflammation, and
hence the -403A allele, which increases the RANTES expres-
sion, appears to help in its control.
With CCR2 V64I SNP we noticed a nonsignificant trend
of increased frequency of 64I allele in patients with interme-
diate uveitis as compared to controls (p=0.03, pc=0.09). This
64I allele was also noted to be the predictor of elevated in-
traocular pressure. Patients with this allele had worse VA after
18 months when compared to patients with the wild-type geno-
type.
In the CCR2 V64I polymorphism, although this amino
acid change is conservative, various studies have shown that
the 64I allele may be a protective factor in immune-mediated
diseases like sarcoidosis and multiple sclerosis [36,56,57].
However the authors were unable to explain the process that
would confer protection against disease with the 64I muta-
tion, as no functional changes have yet been identified [58].
Our data suggested that the 64I mutation could be an in-
dependent risk factor for the development and complications
©2007 Molecular Vision Molecular Vision 2007; 13:388-96 <http://www.molvis.org/molvis/v13/a42/>
TABLE 6. SUMMARY OF SIGNIFICANT ASSOCIATIONS BETWEEN THE CHEMOKINE POLYMORPHISMS AND IDIOPATHIC POSTERIOR SEGMENT UVEITIS
     Phenotype                        Genotype                 p value
-------------------   --------------------------------------   -------
                      MCP-1 -2518 AA   MCP-1 -2518 AG & GG
                      n=82             n=59
Mean age of onset     41 years         33 years                pc=0.003
of *IPSU
                      RANTES -403GG    RANTES -403 GA & AA
                      n=86             n=55
Severe inflammatory   38% (33)         20% (11)                pc=0.04
episodes
                      CCR5 wt/wt       CCR5 del/wt & del/del
                      n=109            n=32
Meanv Visual acuity   6/9              6/6                     pc=0.028
after 18 months
                      CCR2 VV          CCR2 VI & II
                      n=116            n=25
Meanv Visual acuity   6/9              6/15                    pc=0.04
after 18 months
Raised intra-ocular   27% (31)         60% (15)               pc=0.007
pressure
                      CCR5 -59029 GG   CCR5 -59029 GA & AA
                      n=30             n=111
On long term          20% (6)          40% (44)                pc=0.051
corticosteroid
treatment
This table shows the effect of chemokine SNPs on the phenotype of idiopathic posterior segment uveitis. Logistic regression model was used
to perform the statistical calculations. Results show that chemokine SNPs can affect the phenotype of idiopathic posterior segment uveitis and
can be predictors of severity and complications. Asterisk indicates idiopathic posterior segment uveitis.
393of uveitis in Caucasians. This is in contrast with other studies
of systemic immune-mediated diseases [36,56,57], where
whenever the association is present, this 64I allele has found
to be protective. However, at least in age related macular de-
generation this 64I allele has been implicated as a risk factor
[59]. One explanation for this is that, the 64I mutation has
been noted to increase the stability of the CCR2A isoform
[60]. This in turn leads to higher cell surface expression of
CCR2A (but not CCR2B isoform) as compared to the V64
allele. These two isoforms are alternatively spliced variants
of a single CCR2 gene. Although CCR2B is normally present
in greater amount, it is possible that increased CCR2A isoform
levels due to 64I mutation cause the CCR2A isoform to play a
greater role. Given the lack of enough evidence of functional
effects of V64I mutation it is more likely that the effects are
seen as a result of a yet to be identified gene linked to CCR2-
64I that encodes a polymorphic site that plays a role in the
immune response in IPSU.
As noted by other studies [61], the CCR2 V64I was tightly
linked with CCR5 -59029, and del. 32. 64I homozygosity was
not found in subjects with the CCR5 -59029G allele, while -
59029G homozygosity was not observed in subjects with the
CCR2 64I allele. Also, subjects homozygous for CCR2 64I
were never homozygous for CCR5 del. 32. The del. 32 in CCR5
is common in Caucasians as compared to other ethnic groups
and plays an important role against human immunodeficiency
virus (HIV) infection and progression to acquired immune
deficiency syndromes (AIDS). However, its role in immune-
mediated disease is not clear. The presence of the deletion
results in a truncated form of the functional receptor, and ho-
mozygotic carriers of this mutation fail to express CCR5 on
their cell surface. As in other studies, there was a strong link-
age between CCR5 del. 32 and CCR5 -59029 in our study. All
patients with del/del phenotype were homozygous for the -
59029 G allele. Similarly all AA homozygous for -59029 were
also homozygous for the wild-type allele. In our study there
was no association found between these two SNPs and the
risk of developing PSU. However the del. 32 was associated
with a better final visual acuity after 18 months. The mean
final VA of patients having the del. 32 allele was better than
patients with no mutation. If the del. 32 leads to under expres-
sion of the CCR5 receptors, the presence of this mutation might
confer protection against a more severe form of inflamma-
tion, and thus patients with this mutation would be expected
to have a better visual outcome.
CCR5-59029 A allele is a pro-inflammatory mutation. It
has been shown to be an independent risk factor for diabetic
nephropathy in patients with type 2 diabetes [61], and acute
kidney graft rejection in patients with a donor kidney [62].
We found that the A allele was associated with the continuous
need for systemic corticosteroids to control the inflammation,
and we also noted a non-significant trend of higher A allele
frequency (53%) among patients with intermediate uveitis re-
quiring systemic steroids (n=47) compared to 33% in patient
not requiring systemic steroids (n=30; p=0.02, pc=0.06 sug-
gesting that this polymorphism has an effect on the severity of
the inflammatory process). These results show polymorphisms
that decrease CCR5 expression improve the visual outcome.
On the other hand, polymorphisms that decrease RANTES,
which is a ligand of CCR5, are associated with poor visual
outcome. These two results seems contradictory, but it should
be noted that CCR5 is not just a receptor of RANTES, but
also of MIP-1α and MIP-1β[63]. CCR5 shows maximum ac-
tivity toward MIP-1α, and this ligand plays an important role
in uveitis [64]. So while CCR5 may be involved in recruiting
the activated T cells and macrophages toward the site of uvei-
tis through MIP-1α, RANTES may be involved in the
immunomodulation and suppression of uveitis. CCR2 and
CCR5 genes are located on chromosome 3p21, and the SNPs
studied here also show a strong degree of linkage. These mod-
erate associations noted between IPSU and CCR2 and CCR5
SNPs indicate that a locus for genetic susceptibility for IPSU
may be located on chromosome 3 in close proximity to these
SNPs.
In conclusion, this study suggests the involvement of cer-
tain chemokine gene polymorphisms that can influence dis-
ease outcome in patients with IPSU. We propose that RANTES
-403G/A SNP, and polymorphisms in CCR5 and CCR2 genes
can affect the outcome of the disease. Further studies will be
necessary to determine whether patients with alleles indica-
tive of more severe disease may benefit from earlier treatment
with more aggressive therapy to try and prevent visual loss.
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